ROCHESTER, N.Y., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Maurice Zauderer, Ph.D., President and Chief Executive officer, will participate in a Clinical Trials Roundup Session at the Virtual Huntington Study Group (HSG) Meeting at 3:15 p.m. ET on Friday, November 5, 2021. In addition, Elizabeth E. Evans. Ph. D., Chief Operating Officer and Senior Vice President, Discovery and Translational Medicine, will present the poster “SIGNAL Phase 2 Study Suggests that Pepinemab, Anti-SEMA4D Antibody, Provides Cognitive Benefit In Early Manifest Huntington’s Disease.”
Vaccinex to Present at the Virtual Huntington’s Study Group Meeting on November 4-6, 2021
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
